European League Against Rheumatism
EULAR - a vehicle for communication p. 3
EULAR - a vehicle for communication; the role of ILAR p. 8
Overview on the Scientific Basis of Rheumatic Diseases
Molecular and cellular basis of rheumatoid joint destruction p. 15
Euphenic prevention of rheumatoid arthritis p. 20
Molecular concepts in the approach to therapy p. 25
Sjogren's syndrome. The crossroads of autoimmunity and lymphoid malignancy p. 31
Quo vadis, pediatric rheumatology? p. 36
The spondylarthropathies p. 41
Chlamydia-induced arthritis. Clinical features, diagnosis and therapy p. 49
Update on osteoporosis p. 63
The patient, her disease, and her environment. How to make life easier for the rheumatic patient p. 70
Immunological and Biochemical Background of Inflammation, Cartilage Damage and Joint Destruction
Immunological mechanisms
T-cell subsets in rheumatoid arthritis p. 79
CD5-carrying B-cells in rheumatoid arthritis p. 82
Purification of 205-kDa synovial protein stimulatory for T cells p. 85
Molecular development of the B-cell repertoire in systemic autoimmunity p. 91
IgM rheumatoid factors in rheumatoid inflammation: no apparent restriction in germline immunoglobulin and relatively little somatic mutation p. 94
Are HLA-B27-positive individuals immunologically unique? p. 98
Experimental arthritis models have revealed the critical significance of immunity to the 65-kDa heat shock protein in human arthritic diseases p. 102
Elicitation and modulation of autoimmune reactions to cartilage-derived collagen II in experimental and human arthritis p. 105
Progressive polyarthritis and ankylosing spondylitis produced by proteoglycan antigens in Balb/c mice p. 108
Mast cells and histopathology of the rheumatoid lesion p. 112
Mediators of inflammation
TNF[alpha] and TNF receptor expression and regulation in rheumatoid arthritis p. 115
The contribution of elevated intra-articular pressure to the pathogenesis of chronic synovitis p. 118
Lipoxygenase products in inflammatory joint disease p. 124
Neural influences in musculoskeletal diseases p. 127
Neuropeptides in joint inflammation p. 132
Neuroendocrine changes in inflammatory arthritis p. 135
Neurogenic inflammation, capsaicin and counterirritation p. 137
Processing of nociceptive information in the central nervous system of rats with joint-inflamed induced hyperalgesia p. 141
Substance P in rheumatic diseases: clinical implication p. 144
Sex hormones and rheumatic diseases p. 148
Trace elements and vitamin E in rheumatoid arthritis (RA), inflammation vs. diet p. 153
Cartilage damage
The role of cartilage proteoglycans in the pathogenesis of arthritis p. 157
Synovial fluid and serum markers of cartilage degradation in human arthritis p. 161
Animal models in osteoarthritis research p. 163
Type II collagen gene mutations in familial osteoarthritis (OA) p. 165
Biochemical factors in osteoarthritis p. 168
Biochemical backgrounds of joint destruction in osteoarthritis p. 171
Do cytokines play a role in the joint destruction in osteoarthritis? p. 175
Effects of NSAIDs on cartilage proteoglycan and synovial prostaglandin metabolism in relation to progression of joint deterioration in osteoarthritis p. 177

The effects of NSAIDs on the course of osteoarthritis p. 184
Osteophytosis: radiographic perspective p. 189
What is an osteophyte? p. 192
Why do osteophytes form? p. 195
Osteophytes and other bone changes in osteoarthritis p. 198
Osteophytes and 'enthesophytes' of the knee joint: differences and similarities p. 202
Hormonal and metabolic effects on osteophyte formation p. 206
Treatment of osteophytes. Necessary or not? p. 209
MR of the hip with emphasis on avascular necrosis p. 211
MR imaging of the hand and wrist p. 215
Clinical Spectrum of Rheumatic Diseases
Autoimmune diseases
Subgroups and symptom clusters in autoimmune diseases p. 219
Overlap of the polysystemic autoimmune diseases p. 222
Subgroups and symptom clusters in autoimmune diseases p. 225
Serological markers of clinical subsets in connective tissue diseases p. 230
Adult and juvenile rheumatoid arthritis
Mortality in rheumatoid arthritis: prediction by poor clinical status p. 234
Progression in rheumatoid arthritis p. 238
Generalized secondary amyloidosis in rheumatoid arthritis p. 241
Bone and joint oddities mimicking juvenile chronic arthritis p. 245
Prognostic factors in juvenile arthritis complicated with amyloidosis p. 247
Enthesopathies
Enthesitis and tendon inflammation. What type of rheumatic disease? p. 250
Enthesopathy: the common pathologic hallmark of seronegative spondyloarthopathies (SNSA) p. 251
Enthesitis and tendinitis in ankylosing spondylitis p. 254
Possible interaction between the infectious agents and the host in some rheumatic disorders p. 259
T-cell responses in reactive arthritis p. 263
Juvenile reactive arthritis (JREA) nosologic lines and diagnostic problems p. 266
Infection and arthritis
Arthritis and HIV infection p. 269
Treatment of Lyme arthritis p. 272
Lequesne’s questionnaire (LQ) in the assessment of knee osteoarthritis (OA) severity p. 275

Epidemiology of osteoporosis p. 278
Prevention and treatment of osteoporosis p. 282
Fibromyalgia and soft tissue rheumatism
Does fibromyalgia exist? p. 284
Fibromyalgia: a neuroendocrinologic disease? p. 287
Mechanical hyperalgesia in tennis elbow p. 290
Non-pharmaceutical treatment of fibromyalgia: influence on quality of life p. 293

Advances in Therapeutic Modalities in Rheumatology
Disease-modifying antirheumatic drugs
The controlled clinical trial: the gold standard with feet of clay p. 299
Outcome methods for evaluating DMARD efficacy in rheumatoid arthritis p. 302
Assessing function in clinical trials p. 304
Safety and toxicity of disease-modifying antirheumatic drugs p. 306
Slow-acting drugs do not effect the outcome of rheumatoid arthritis p. 309
DMARDs: do they retard progression of radiological joint damage in rheumatoid arthritis? p. 312
Early DMARD treatment of rheumatoid arthritis p. 316
T-cell vaccination in rheumatoid arthritis p. 318
Cyclosporin in rheumatoid arthritis p. 320
Systemic and topical NSAIDs
The relative toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) p. 322
Tolerance of NSAIDs: pseudo-allergic and allergic reactions p. 325
Topical NSAIDs p. 328
Significance of topical NSAIDs in the context of overall treatment methods in rheumatic disease p. 330
Pharmacokinetic studies of topical NSAIDs p. 333
Topical therapy as alternative treatment of osteoarthritis p. 336

Intraarticular therapy
European experience with intra-articular corticoid therapy p. 341
Radiosynoviorthesis p. 344
Intra-articular therapy: chemical synoviorthesis with natriummorrhuat (Varicocid) and other substances p. 349

Surgical therapy
Experiences in hip endoprosthetics with special reference to rheumatoid arthritis p. 352
The Butel iso-elastic hip prosthesis p. 354
Operative intervention in rheumatoid arthritic knee p. 355
EULAR knee arthroplasty assessment project - results with cemented total condylar prostheses
A comparative study of two different knee systems in the same patient
Cementless total knee replacement arthroplasty in inflammatory diseases with special reference to AGC
The present status of total elbow replacement
Implants in the hand in rheumatoid arthritis
Surgery in ankylosing spondylitis
Physiotherapy in rheumatology
Controlled trials in physiotherapy - a Hungarian approach
Effects of physical applications on experimental models of inflammation
Hydrotherapy and balneotherapy: State of the art
Kinesitherapy in the treatment of rheumatic diseases
The most effective rehabilitation medicine: home treatment in some of the common rheumatological conditions - a controlled study
Social Aspects, Teamwork and Education in Rheumatology
Social aspects
Science and the patient
Significant life events (LE): do they modify the short- and medium-term course of rheumatoid arthritis (RA)?
Barbara and her juvenile chronic arthritis: a doctor's story
My own story about a life with juvenile chronic arthritis (JCA)
Surgery and ankylosing spondylitis
Teamwork
Specialization and collaboration in the treatment of rheumatoid arthritis patients
Arthritis care at the district level
Improvement of nearby domicile care for patients suffering from rheumatism by the German League Against Rheumatism (GLAR) - report on a model implemented by the Schleswig-Holstein branch of the GLAR
The rheumatoid arthritis school - a form of teamwork
The role of the pharmacist in the rheumatology health-care team
Effects of group counselling for rheumatoid arthritis patients on measures of psychological adjustment to illness
Contributions by self-help groups to the quality of life within a society in transformation
Education in rheumatology
EULAR/WHO guidelines for an undergraduate program in rheumatology
European exchange in postgraduate education in rheumatology
Cooperation between pharmaceutical companies and physicians to improve the medical care of rheumatic patients in daily clinical practice
ILAR resource center for educational material
EURORITS program of study visits for young rheumatologists
Postgraduate rheumatology education in Europe - report of a questionnaire survey
Postgraduate courses on rheumatology for nursing staff
Index of authors

Table of Contents provided by Blackwell's Book Services and R.R. Bowker. Used with permission.